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OBJECTIVE: Osteonecrosis of the jaw (ONJ) is a poten-
tially severe adverse effect of various medications (bis-
phosphonates, anti-resorptive, and anti-angiogenic
drugs). ONJ pathogenesis is still unclear although some
risk factors have been recognized. Of these, rheumatoid
arthritis (RA) has been hypothesized as a potential risk
factor for developing ONJ. This observational study will
describe a multicenter case series of patients affected
with RA and ONJ, and it will attempt to evaluate the
association between features of ONJ and pharmacologi-
cal, systemic, and site variables.
METHODS: Demographic, pharmacological, and clinical
data from 18 RA patients with ONJ were collected and
registered from three Italian centers (i.e., Palermo, Ver-
ona, and Padua) from 2004 to 2013.
RESULTS: Sixteen (88.9%) patients were in therapy for
RA: 9 of 18 (50.0%) with systemic steroids, 3 of 18 (16.7%)
with methotrexate, and 4 of 18 (22.2%) with both medica-
tions. Two patients were not receiving treatment for RA.
All patients took NBPs for secondary osteoporosis (aver-
age NBP duration of 69 months, range: 20–130): Fifteen
(83.3%) patients were treated with single NBPs, while
three (16.7%) with different molecules; one patient was
also treated with denosumab. Mandible was affected
more frequently (66.7%) than maxilla (33.3%); one
patient presented multiple ONJ events.
CONCLUSIONS: This is the first multicenter case ser-
ies in the international literature regarding our topic.
Focusing on our data, it could be hypothesized that
patients with RA may be more susceptible to ONJ than
the majority of osteometabolic patients. In our opinion,
it could be important to monitor also denosumab or
other biological drug side effects.
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Introduction
Rheumatoid arthritis (RA) is a systemic, inﬂammatory,
autoimmune disorder, characterized by a progressive joint
destruction and various systemic manifestations (e.g., hema-
tological, neurological, respiratory, and cardiovascular
events). RA is more frequent in women with a prevalence
of about 1%, thereby suggesting a role for sex hormones.
The annual incidence rate of RA varies between 20 and 50
cases per 100 000 in North American and North European
countries, and it may be lower in South European countries
(Alamanos et al, 2006; Carbonell et al, 2008); unfortu-
nately, incidence studies from other countries are not cur-
rently available. RA is the most common form of
inﬂammatory arthritis with the highest propensity to over-
step in the cases of synovitis, inﬁltrating articular bone and
cartilage. Three types of alterations in bone mass can be rec-
ognized in patients with RA: periarticular bone loss, joint
erosions, and generalized bone loss. Key drugs in the thera-
peutic regimens of RA are glucocorticoids (GCs), which
have demonstrated a slowing of radiographic progression
(Jacobs et al, 2014). Furthermore, prescription the disease-
modifying anti-rheumatic drugs (DMARDs), such as
methotrexate (MTX), is another essential regimen for RA
therapy and the drug methotrexate is widely used (Dim-
itroulas et al, 2013). The event of generalized bone loss is a
secondary osteoporotic condition, and it can be frequently
aggravated by (i) therapy with GCs and/or MTX (Salute),
commonly used to treat RA; (ii) physical inactivity
(Vasquez et al, 2013), typically due to RA pain; and
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(iii) inﬂammatory disease mechanisms (e.g., elevated levels
of systemic cytokines) (Bartold et al, 2005). In particular,
the osteoclast pathway is galvanized by an alteration in
immune status, accompanied by chronic inﬂammation; the
latter is a typical condition in periarticular osteoporosis and
local bone destruction around the joints (Ono et al, 2013).
It has been reported that in an observed population, 94.6%
of the patients were given a DMARD therapy; 82.5% of the
patients receiving methotrexate additionally received folic
acid; and 65.9% of the patients received calcium and vita-
min D (Hartmann et al, 2008) and glucocorticoids. In order
to prevent or treat primary or secondary osteoporosis,
patients with RA take bisphosphonates (BPs):
Nitrogen-containing bisphosphonate (NBP) or non-nitro-
gen-containing bisphosphonate (NBP) are frequently used.
Alendronate has been the most prescribed oral NBP formu-
lation (Piscitelli et al, 2014), and to date, it has been fre-
quently related to the severe BP-related adverse drug
reaction named as osteonecrosis of the jaw BRONJ (bispho-
sphonate-related ONJ) (Di Fede et al, 2013). Firstly,
BRONJ was observed by Marx and Stern in 2002. Exten-
sive case series regarding BRONJ were published in 2003
by Marx and in 2004 by Ruggiero et al (Marx, 2003; Rug-
giero et al, 2006); currently, an increasing number of publi-
cations relating to BRONJ are available in the literature.
Recently, BRONJ was deﬁned by Bedogni et al as a ‘pro-
gressive destruction and death of bone that affects the
mandible and/or maxilla of patients, exposed to treatment
particularly with NBPs, in the absence of a previous radia-
tion treatment’ (Bedogni et al, 2012). In subjects exposed
to NBPs, following a localized trauma, such as tooth extrac-
tion, the jaw could generally fail to heal, leaving the bone
exposed in many cases (Capsoni et al, 2006). There are,
however, numerous reports describing ONJ with symptoms
and/or minor signs, but in the absence of bone exposure
(Mawardi et al, 2009; Fedele et al, 2010; Bedogni et al,
2014). Bone lesions can be observed more frequently in the
mandible and less in the maxilla (Otto et al, 2012; Vescovi
et al, 2012; Khan et al, 2015); both mandible and maxilla
have been found in different percentages (5–11.1%) (Otto
et al, 2012; Gammelager et al, 2013). Furthermore, other
anti-angiogenic (e.g., bevacizumab) and/or anti-resorptive
(e.g., denosumab, sunitinib) drugs have been associated
with ONJ (Fangusaro et al, 2013; Fusco et al, 2015; Fedele
et al, 2015).
The epidemiology of ONJ remains unclear due to the
inconsistency and the limitations of available studies.
These include a lack of a speciﬁc ICD code; under-report-
ing in Surveillance Drug Systems; a recent introduction of
preventive measures; case adjudication restricted to
exposed ONJ; short-term observation; and a lack of cumu-
lative long-term incidence rates (Campisi et al, 2014).
Very recently, English authors have estimated that the
incidence of ONJ in the oncological and osteometabolic
population is approximately 10 cases/million/year (Rogers
et al, 2015). A wide-ranging incidence of ONJ from 0%
to 27.5% has been reported for individuals exposed to
intravenous BP (Kuhl et al, 2012). In patients receiving
oral NBPs, ONJ data should be treated with caution (Reid,
2009). Generally, a prevalence of ONJ ranging from
0.001% to 0.4% (Lo et al, 2010; Conte-Neto et al, 2012;
Malden and Lopes, 2012; Landesberg and Taxel, 2013)
has been reported in patients with RA. While the patho-
genesis of ONJ is unclear, various risk factors are not well
recognized and they are usually categorized into three
groups: drug-related, local, and demographic/systemic risk
factors (Ruggiero et al, 2006; 2007). Of the systemic risk
factors, rheumatoid arthritis (RA) has been markedly con-
sidered (Malden et al, 2009; Park et al, 2010), although a
comprehensive study has yet to be performed.
Rationale
The case reports of a few patients with RA (Junquera
et al, 2009; Conte Neto et al, 2011; Conte-Neto et al,
2011, 2012; O’Ryan and Lo, 2012; Ebker et al, 2013;
Fasciolo et al, 2014; Nori et al, 2014; Alsalleeh et al,
2014; Manzon et al, 2014) have been described in the lit-
erature. In addition to discussing the prescription of NBPs
for treating or preventing cases of osteopenia/osteoporosis,
further factors leading to ONJ in patients with RA have
been hypothesized: chronic inﬂammatory alterations
(Conte Neto et al, 2011), the immunosuppressive action
of corticosteroids (Coutinho and Chapman, 2011), and
MTX (Herman et al, 2004) predisposing to local infec-
tions (Fleischmann et al, 2006). In order to reduce any
bias and to verify a possible link between RA and ONJ,
multicenter studies are required.
Methods
Study design
A retrospective cohort study was reported according to Strengthening the
Reporting of Observational Studies in Epidemiology (the STROBE) rec-
ommendations (von Elm et al, 2014). The ethical committees of the par-
ticipating centers approved the study (N 4/2012 18-04-2012), and patient
consent was obtained where speciﬁcally required.
Setting
Researchers at the Universities of Palermo, Verona, and Padua designed
the study and sent a collaboration proposal to their centers of oral medi-
cine and/or maxillofacial surgery with a special interest in the diagnosis
of ONJ in patients affected by RA.
Participants
Selection and eligibility criteria. Patients, referred to the participating
centers between January 2004 and December 2011, were eligible for our
study if (i) they were affected by RA; (ii) they had previously had, or
were currently having, treatment with bisphosphonates and/or
denosumab; (iii) they had exposed ONJ (deﬁned as the presence of long-
standing – >8 weeks – transmucosal exposure of necrotic jawbone
(Ruggiero et al, 2009)) or nonexposed ONJ (deﬁned as the presence of
otherwise unexplained jawbone pain, ﬁstula, swelling, mobile teeth, or
mandibular fracture, as deﬁned by Fedele et al (2010)); (iv) they had no
history of head–neck radiotherapy; and (v) there existed CT scan imaging
(spiral or cone-beam) of the affected jawbones. Only patients with CT
scans performed within 6 months from clinical phenotyping were
included, in order to have a concordance between clinical manifestations
and CT ﬁndings. Dentascan reformatted images were not considered as
they do not accurately display the ramus of the mandible and the
midfacial bones.
Criteria for the exclusion were off-label use of BPs and the presence
of associated tumor growth in the jaws. ONJ case adjudication through-
out all the centers was performed by multidisciplinary teams that
included BP prescribers and specialists in oral medicine and/or in max-
illofacial surgery. Each report was supported by a qualitative case-by-case
assessment procedure, which was performed by an ofﬁcially recognized
drug expert.
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Data collection and variables
The hospital notes of consecutively diagnosed patients with ONJ were
retrospectively reviewed between June 2012 and September 2013. The
following data (clinical, radiological measurement) relevant to the study
were extracted by local clinical teams and entered into a predeﬁned elec-
tronic case report form by one clinician at each institution.
The following clinical measurements were collected from the clinical
charts: (i) age; (ii) sex; (iii) underlying bone disorders and comorbidities;
(iv) NBP type; (v) duration of NBP treatment; (vi) NBP cumulative dose;
(vii) the simultaneous or select use of anti-resorptives (e.g., denosumab);
(viii) the concurrent use of steroids and/or methotrexate; or (ix) other
drugs, such as anti-angiogenic agents (i.e., sunitinib and bevacizumab);
(x) the time period leading up to ONJ onset; (xi) the presence of known
risk factors for ONJ (tooth extraction, dental or periodontal infection, an
ill-ﬁtting prosthesis, and dental implant surgery); (xii) the ONJ site; (xiii)
the presence of exposed bone; and (xiv) the presence of minor clinical
signs and symptoms.
Radiological measurements were analyzed by panoramic radiograph
and computed tomography (CT).
The staging of the disease was based on the current clinico-radiologi-
cal staging system, as proposed by SICMF-SIPMO (Bedogni et al,
2013).
Statistical analysis
The two responses of the study were bone exposure, coded as negative
or positive, and the ONJ stage, coded according to SICMF-SIPMO and
dichotomized as stage 2 or 3 vs stage 1 (Bedogni et al, 2013). To sum-
marize demographic data and outcomes, categorical values were
expressed as counts and percentages (%). Quantitative variables, such as
NBP cumulative dose (mg) and NBP duration (months), were expressed
as the median value and the interquartile range (the 25th and 75th per-
centiles). At univariate analysis, the association of both responses with
pharmacological, systemic, and clinical variables and the association
between either corticosteroid therapy or tooth extraction with NBP fea-
tures were tested using Fisher’s exact test. Furthermore, crude odds ratios
(OR) and 95% conﬁdence intervals (CI) were calculated as association
measures. NBP duration and cumulative dose were dichotomized using
the median value. Alendronate was chosen as a reference for the type of
administered NBP. Multivariate analysis was not performed, in the
absence of statistically signiﬁcant variables at univariate analysis. A P-
value <0.05 was chosen to represent the statistical signiﬁcance. Data were
analyzed using STATA SE, version 14.1.
Results
Details of the study population
Eighteen patients affected by RA and ONJ were consid-
ered eligible (Table 1): sixteen patients were females and
two males, and the median age was 69 years (interquartile
range: 63–72 years). Sixteen (88.9%) patients were in
therapy for RA: 9 of 18 (50.0%) with systemic steroids, 3
of 18 (16.7%) with methotrexate, and 4 of 18 (22.2%)
with steroid and methotrexate. Two patients with RA
declared that they were not currently receiving any treat-
ment. All patients suffered from secondary osteoporosis
and 11 of 18 (61.1%) showed further morbidities (e.g.,
diabetes, coagulopathy). All had been treated with bispho-
sphonates. More than half (11, equal to 61.0%) of the
patients were treated with alendronate, and three of them
also received another NBP. Four patients (22.2%) were
treated with ibandronate, 2 (11.1%) with risedronate, and
1 (5.6%) with zoledronate. In the subgroup of patients
who had only used alendronate, the median cumulative
dose was 15 120 and the median duration of NBP therapy
was 69 months. The mandible was affected by ONJ more
frequently (66.7%) than the maxilla (33.3%), and one
patient presented more than one localization of ONJ
(mandible and maxilla). ONJ appeared as exposed in 11
(61.1%) patients and as the nonexposed variant in 7
(38.9%) subjects. Regarding the ONJ staging, according to
Bedogni et al (2012), four patients had stage 1 ONJ
(22.2%), 11 patients had stage 2 (61.1%), and three
patients had stage 3 (16.7%). Tooth extraction (due to
dental/periodontal diseases) was identiﬁed in 9 (50.0%)
patients as a trigger ONJ event. There was evidence of
Table 1 Demographic data and outcomes
AR + BRONJ analyzed patients 18
Median age (years) 69
Interquartile range (years) 63–72
Mean age  SD (years) 68.0  8
Gender n (%)
Female 16 (88.9)
Male 2 (11.1)
Yes No
Other comorbidities 11 (61.1) 7 (38.9)
AR therapy
Corticosteroid therapy 13 (72.2) 5 (27.8)
Methotrexate therapy 7 (38.9) 11 (61.1)
Other drugs
Denosumab therapy 1 (5.6) 17 (94.4)
Type of administered NBP n (%)
Alendronatea 11 (61.1)
Ibandronate 4 (22.2)
Risedronate 2 (11.1)
Zoledronate 1 (5.6)
Mono-NBP 15 (83.3)
Poly-NBPs 3 (16.7)
Time and dose of NBP exposure Range Median (Q1–Q3)
NBP duration (months) 20–130 69 (48–99)
NBP cumulative dose (mg) 5–36 400 15 120 (0–27 720)
BRONJ site n (%)
Mandible 12 (66.7)
Maxilla 6 (33.3)
Yes No
Bone exposure 11 (61.1) 7 (38.9)
BRONJ staging (Bedogni et al, 2013) n (%)
Stage 1 4 (22.2)
Stage 2 11 (61.1)
Stage 3 3 (16.7)
Trigger event (local risk factors for BRONJ)
Yes
n (%)
No
n (%)
18 (100.0) 0 (0.0)
Tooth extraction 9 (50.0)
Periodontal infection 5 (27.8)
Prosthetic trauma 1 (5.6)
Implant infection 3 (16.7)
a3 of 12 patients treated with Alendronate received also another NBP.
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periodontal chronic disease in 5 (27.8%) subjects, pros-
thetic trauma in 1 (5.6%) case, and dental implant infec-
tion in three other cases (16.7%). Of note, implant surgery
was carried out before NBP administration in all cases.
Other clinical and pharmacological records of the sample
are shown in Table 2.
When bone exposure was associated with pharmacolog-
ical, systemic, local, and clinical variables, no signiﬁcant
association was found (Table 2). Neither treatment with
corticosteroid therapy nor tooth extraction as an ONJ trig-
ger event was signiﬁcantly associated with NBP features
(Table 3).
Discussion
Osteonecrosis of the jaw (ONJ) is a rare and serious
adverse side event, particularly related to the administra-
tion of NBPs. Its epidemiology and pathogenesis remain
for the most part unclear although signiﬁcant improve-
ments have been made regarding its deﬁnition, diagnosis
and staging, prevention strategies, and treatment; addi-
tional risk factors have yet to be recognized.
Generally, the effective risk of ONJ in patients treated
with NBPs for osteometabolic diseases is not particularly
well known, in part due to the paucity of crucial informa-
tion. The latter include the exact total number of patients
exposed to NBPs and the precise interplay of the elevated
number of potential risk factors implicated. Even less is
known about ONJ risk in patients with RA. NBPs are the
main drugs associated with ONJ, but they are not the only
ones. Indeed, denosumab, which has recently been used to
treat secondary osteoporosis, is also considered to be ONJ
related. Systemic steroids and methotrexate (MTX) are
generally prescribed, also in combination, to manage
chronic diseases such as RA, a systemic autoimmune dis-
ease characterized by a progressive joint destruction and a
variety of systemic manifestations resulting from chronic
inﬂammation. Although RA has been proposed as one of
the risk factors for ONJ (Conte-Neto et al, 2011), no RCT
has been published for establishing the effective associa-
tion between ONJ and RA, and fewer papers discussing
epidemiological data have been produced.
Several relevant factors linking RA and ONJ have been
discussed (Conte Neto et al, 2011): the role of steroids
and other immunosuppressive agents, such as MTX for
the inhibition of bone remodeling; NBP could increase the
arthritic process, thereby increasing ﬂogosis; the anti-
angiogenic activity of NBP determining the loss of blood
vessels; inﬂammation by RA due to its deleterious effects
on bone tissues directly or by mediators; concomitant dis-
eases, such as periodontitis and osteomyelitis, which are
common in patients with RA; and NBP and/or MTX toxi-
city theory. NBPs exclusively affect the phagocytic cells
and not other types of cells, and the local immune
response could also be compromised. Indeed, because bis-
phosphonates do not affect neutrophils, the risk of sys-
temic infection is low. The reduced function of monocytes
and macrophages could become critical for the develop-
ment of ONJ (Pazianas, 2011).
Some of aforementioned and controversial hypotheses
have been recognized in our study: The majority of the
patients with ONJ (88.9%) were undergoing therapy with
steroids and/or MTX to treat RA, and many local inﬂam-
matory features were recognized; on the other hand, in 5
of 18 (27%) who did not take GCs, other factors (such as
MTX therapy or ﬂogosis activation) could play a predomi-
nant role. Moreover, there were other two subjects who
had never been in treatment for RA either with systemic
corticosteroids or MTX and they presented even more
advanced conditions of local ﬂogosis than the patients
with RA undergoing therapy. At this point, the authors
consider them to be very important in taking them into
account regarding an ONJ prognosis. Indeed, O’Ryan and
Lo (2012) have recently observed that patients with ONJ
taking oral BPs with relevant comorbidities, such as RA,
had a lower probability of healing and a longer median
time in healing than patients without comorbidities.
Some years ago, an extended literature review (Conte-
Neto et al, 2012) was conducted with the aim of evaluating
important issues relating to patients with RA who had
developed ONJ, including demographic, clinical, and treat-
ment aspects. The goal of this study was to establish the
comparative associations between patients without RA but
who had developed oral BRONJ. Different research was
compared with different descriptive procedures and consid-
ered variables. The sample of data discussed in this study
was collected in accordance with the same research proto-
col, applying and aggregating data from different regions (a
multicenter study). Therefore, this reduced the probability
of missing data, thereby producing a homogeneous sample.
Patients with RA who developed ONJ lesions after an oral
Table 2 Statistical signiﬁcance of the univariate associationa between
bone exposure and SICMF-SIPMO staging with pharmacological, sys-
temic, and clinical variables
Bone exposure SICMF-SIPMO staging
Type of administered NBP 0.589 0.112
NBP cumulative doseb 1.000 0.576
NBP durationc 1.000 1.000
Implant infection 1.000 1.000
Periodontal infection 0.596 0.278
Prosthetic trauma 0.3891 1.000
Tooth extraction 1.000 0.082
Other comorbidities 1.000 1.000
Corticosteroid therapy 0.326 1.000
Methotrexate therapy 0.637 1.000
Denosumab therapy 1.000 1.000
BRONJ site 0.627 1.000
aFisher’s exact test, P-value; P-values < 0.05 were statistical signiﬁcant.
bCumulative dose >15 120 vs ≤15 120 (median value).
cDuration >69 vs ≤69 (median value).
Table 3 Statistical signiﬁcance of the univariate associationa between
steroid assumption and tooth extraction with pharmacological variables
Steroids Tooth extraction
Type of administered NBP 1.000 0.506
NBP cumulative doseb 1.000 1.000
NBP durationc 1.000 1.000
aFisher’s exact test, P-value; P-values < 0.05 were statistical signiﬁcant.
bCumulative dose >15 120 vs < or =15 120 (median value).
cDuration >69 vs < or =69 (median value).
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NBP intake were usually female, 60+ years old, as has
already been observed by other researchers (Conte-Neto
et al, 2011). In the patient group in this study, alendronate
– an oral NBP – was found to be that most associated
(61.1%) with osteonecrosis. It is also the most prescribed
drug for preventing and treating osteoporosis, as conﬁrmed
by Malden and Lopes (2012). The duration of NBP in the
RA patients with ONJ in this study varied from 1 to
130 months, similar to that previously reported (2–
120 months) (Di Fede et al, 2013) in the osteoporotic case
series. Moreover, it is notable that the longer-term use of
oral NBPs, as is usual for RA therapy, may have a dose
equivalence effect, potentially approximating to that of BP
levels in bone, which is thought to be achieved only
through high-dose intravenous delivery.
Of note, it is interesting to observe the absence of spon-
taneous ONJ in our sample, that is, when any systemic
and/or local risk factors were not recognized: Excluding
the presence of RA, whose hypothesis of ONJ onset was
not deﬁned, one or more ONJ risk factors were recognized
in every patient. Thus, the presence of RA might lead to
an enhanced susceptibility, as previously speculated, even
if evidence for this is currently lacking.
In order to evaluate the site and characteristics of ONJ
in the patients with RA in this study, we observed that the
mandible was most prevalently involved (61.1%) and this
fact has been published by other researchers in the ﬁeld
(Diniz-Freitas et al, 2012; Di Fede et al, 2013). Further-
more, a high percentage of cases (38.9%) did not present
bone exposure, but they did display minor clinical and
radiological signs, according to Bedogni et al (2012).
In conclusion and in light of the data presented in this
study, it could be hypothesized that the patients with RA,
when exposed to NBP, may be more susceptible to ONJ
than the majority of osteometabolic patients. Evidently,
one signiﬁcant limitation of our research is the absence of
RCTs dealing with this issue. This surely points to the
direction of future research.
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